Bernstein Remains a Hold on Pfizer (PFE)
Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $32.00. The ...
Neutral Outlook for Pfizer Amidst Revenue Adjustments and Competitive Pressures
Analyst Tim Anderson from Bank of America Securities reiterated a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at ...
MM&M5d
Rx Rundown: Merck, Biogen, Pfizer and more
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
pharmaphorum2d
A history of Pfizer
Pfizer was founded in 1849 by two recent German immigrants to the USA, Charles Pfizer and Charles Erhart. Both in their mid-twenties, the two men set up what was initially a fine chemicals ...
kalkinemedia1d
Why Did Welch Group LLC Reduce Its Stake in Pfizer (NYSE:PFE)?
Highlights,Welch Group LLC reduced its position in Pfizer,(NYSE:PFE),by over 35% in the fourth quarter.,Institutional ...
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Le Lézard4h
Vaxxas Appoints Leading Global Vaccine Experts as the Company Advances its Needle-Free Vaccination Technology Towards Late-Stage Clinical Trials
Vaxxas, a clinical-stage biotechnology company, today announced the appointments of three globally respected vaccine experts as advisors to its product development and strategy team as the company ...
Medscape1d
Mark J. Alberts, MD
New York Charles E. Argoff, MD, has disclosed the following relevant financial relationships: Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Pfizer ...